The BioMarkId biomarker discovery platform is a technology designed to discover novel biomarkers in complex samples including cells, patient tissue samples and infectious organisms. The technology uses high-sensitivity, high-resolution quantitative mass spectrometry to identify novel biomarkers in client provided or other samples as agreed with the client.
The design of a biomarker discovery project is dependent on client needs; however, all our expertise in quantitative mass spectrometry, biochemistry, cell biology and bioinformatics is integrated into project design to meet the client’s requirements.
Use BioMarkId to indentify novel biomarkers in patient tissues, cells, biofluids or in stem cells. As regards stem cells, the ability to induce pluripotent stem cells is of major significance to the field of regenerative medicine and is of interest in the production of genotype and phenotype specific cells to understand the ontogeny of disease, for drug screening or for clinical use in the treatment of damaged or degenerating tissues. Therefore, BioMarkId can be used to unbiasedly identify determinants of pluripotent cell specification and/or maintenance.
Major applications of the technology include:
- Determination of diagnostic biomarkers in patient samples: use BioMarkId to identify biomarkers for the identification of disease biomarkers suitable for use in the development of diagnostic tests
- Identification of drug efficacy biomarkers: use BioMarkId to discover novel efficacy biomarkers during preclinical testing in animal models and clinical testing of drug candidates to determine their efficiency in clearing an infectious agent in serum or treating a disease.
- Discovery of prognostic biomarkers: use BioMarkId to identify biomarkers that can predict the likely progression and outcome of a disease and hence inform on dosage/intensity of treatment upon appearance of marker in patient sample
- Discovery of stem cell status and cancer stem cell biomarkers: the sub-population of tumor-initiating cells or cancer stem cells is very small and the challenge is to detect them in clinical samples. Identification of novel biomarkers to these cells will facilitate diagnosis and improve the ability of clinicians to predict outcome and/or response to treatment.